ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer

BACKGROUND: One-third of estrogen (ER+) and/or progesterone receptor-positive (PGR+) breast tumors treated with Tamoxifen (TAM) do not respond to initial treatment, and the remaining 70% are at risk to relapse in the future. Estrogen-related receptor gamma (ESRRG, ERRγ) is an orphan nuclear receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhavan, Subha, Gusev, Yuriy, Singh, Salendra, Riggins, Rebecca B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436109/
https://www.ncbi.nlm.nih.gov/pubmed/25971350
http://dx.doi.org/10.1186/s13046-015-0150-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436109/
https://www.ncbi.nlm.nih.gov/pubmed/25971350
http://dx.doi.org/10.1186/s13046-015-0150-9

Ejemplares similares